Cyclic Heavy Menstrual Bleeding Market Report 2026

The cyclic heavy menstrual bleeding market size has grown strongly in recent years. It will grow from $45.7 billion in 2025 to $48.33 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to high prevalence of hormonal disorders, limited awareness of menstrual disorders, reliance on oral medications, underdiagnosis, hospital-based treatment.

The cyclic heavy menstrual bleeding market size is expected to see strong growth in the next few years. It will grow to $62.45 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to advancements in hormonal therapies, growth of minimally invasive gynecology, increasing patient awareness, expansion of specialty clinics, improved diagnostic imaging. Major trends in the forecast period include rising use of hormonal treatment options, increased adoption of minimally invasive procedures, growing awareness of women’s reproductive health, expansion of outpatient gynecology care, focus on long-term symptom management.

The rising incidence of uterine fibroids and polyps is expected to drive the growth of the cyclic heavy menstrual bleeding market in the coming years. Uterine fibroids and uterine polyps are common noncancerous growths that develop in the uterus of women and are a major cause of abnormal and heavy menstrual bleeding. Treatment of fibroids and polyps helps reduce excessive blood loss, regulate menstrual cycles, prevent complications, and improve the emotional well-being of patients affected by menstrual disorders. For instance, in January 2025, according to the Society for Women’s Health Research, a US-based non-profit organization, an estimated 6.5 million women of reproductive age were affected by endometriosis, while approximately 26 million women between the ages of 15 and 50 had uterine fibroids. Despite their high prevalence, research funding for uterine fibroids remains relatively low, ranking among the bottom 50 of more than 300 conditions funded by the National Institutes of Health in 2023. Therefore, the increasing prevalence of uterine fibroids and polyps is contributing to the growth of the cyclic heavy menstrual bleeding market.

Major companies operating in the cyclic heavy menstrual bleeding market are increasingly focusing on procedure-simplification trends, such as single-use and pre-assembled hysteroscopy kits, to improve efficiency, standardize workflows, and support in-office treatment capabilities. These advanced kits combine all necessary components for hysteroscopic evaluation into a single sterile package, reducing setup time and inventory complexity. For instance, in May 2025, Minerva Surgical Inc., a US-based medical technology company specializing in minimally invasive gynecologic solutions, launched the HERizon Hysto-Kit. This single-use, pre-assembled hysteroscopy kit is designed to support office-based evaluation and treatment of abnormal uterine bleeding. The kit includes integrated irrigation and suction tubing, a drape with a fluid collection pouch, and compatibility with Minerva’s disposable hysteroscope and instrument accessories. The HERizon Hysto-Kit enhances procedural efficiency, simplifies supply management, and improves clinical workflows, supporting better point-of-care decision-making for abnormal uterine bleeding management.

In January 2025, Hologic Inc., a US-based provider of advanced women’s health diagnostic and surgical technologies, acquired Gynesonics Inc. for approximately US$350 million. Through this acquisition, Hologic gained access to the Sonata System, a minimally invasive, incision-free device used for intrauterine imaging and radiofrequency ablation of symptomatic fibroids. This acquisition strengthens Hologic’s gynecological surgical offerings and expands its portfolio in minimally invasive fibroid treatment solutions. Gynesonics Inc. is a US-based medical device company known for its proprietary Sonata technology, which integrates real-time intrauterine imaging with targeted fibroid ablation.

Major companies operating in the cyclic heavy menstrual bleeding market are Pfizer Inc., Merck and Co. Inc., Novartis AG, Abbott Laboratories, GlaxoSmithKline Plc, Medtronic Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Reckitt Benckiser Group Plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd.

North America was the largest region in the cyclic menstrual bleeding market in 2025. The regions covered in the cyclic heavy menstrual bleeding market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cyclic heavy menstrual bleeding market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cyclic heavy menstrual bleeding market by increasing costs of imported hormonal drugs, surgical devices, and diagnostic equipment. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported therapies, while Asia-Pacific faces higher procedural costs. These tariffs are increasing treatment expenses. However, they are also supporting domestic pharmaceutical production and localized gynecological care solutions.

The cyclic heavy menstrual bleeding market research report is one of a series of new reports that provides cyclic heavy menstrual bleeding market statistics, including cyclic heavy menstrual bleeding industry global market size, regional shares, competitors with a cyclic heavy menstrual bleeding market share, detailed cyclic heavy menstrual bleeding market segments, market trends and opportunities, and any further data you may need to thrive in the cyclic heavy menstrual bleeding industry. This cyclic heavy menstrual bleeding market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cyclic heavy menstrual bleeding refers to abnormally heavy and prolonged menstrual periods that occur on a regular monthly cycle. This condition can result from a range of factors, including hormonal imbalances, uterine fibroids, polyps, adenomyosis, certain medications, or other underlying medical conditions. Treatment for cyclic heavy menstrual bleeding involves various medical approaches and interventions aimed at managing symptoms and reducing associated complications.

The main types of cyclic heavy menstrual bleeding include polymenorrhea, oligomenorrhea, and metrorrhagia. Polymenorrhea is a menstrual cycle disorder characterized by menstrual periods occurring more frequently than the typical cycle length of approximately 21 to 35 days. Treatment options include medications, hormonal therapies, and surgical procedures, which are administered through routes such as oral and parenteral administration. These treatments are provided across different end-user settings, including hospitals, home care, specialty clinics, and other healthcare facilities.

The cyclic heavy menstrual bleeding market consists of revenues earned by entities by provide diagnostic testing, treatment planning and non-hormonal medications. The market value includes the value of related goods sold by the service provider or included within the service offering. The cyclic heavy menstrual bleeding market also includes sales of sanitary products, hormonal contraceptives, tranexamic acid and nonsteroidal anti-inflammatory drugs (NSAIDs). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.